This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Day, C. Search for Related Content Social Bookmarking                         What's this?

Amylin analogue as an antidiabetic agent

Diabetes Group, Life and Health Sciences, Aston University, Birmingham, B4 7ET, UK, cday{at}mededuk.com

The amylin analogue pramlintide (SYMLIN^®) is the first in a new class of injectable amylinomimetic agents to be approved for the treatment of diabetes. This adjunct to insulin treatment of type 1 and type 2 diabetes has recently been approved for use in the USA. Pramlintide, unlike native amylin is soluble. It acts mainly via central effects (area postrema) resulting in deceased glucagon secretion, slowing gastric emptying and a satiety effect. It is injected subcutaneously separately from insulin, and usually before each of the main meals. It has been shown to improve glycaemic control without causing weight gain but the dose must be titrated slowly in association with appropriate insulin adjustments to guard against insulin-induced hypoglycaemia and nausea. Thus, pramlintide is an injected amylin replacement therapy that can be used with an insulin regimen to improve glycaemic control without weight gain.

Key Words: amylin • pramlintide • type 1 diabetes • type 2 diabetes • injections.

References

• Bailey CJ New drugs for the treatment of diabetes mellitus in DeFronzo RA, Ferrannini E, Keen H, Zimmet P (eds). International textbook of diabetes mellitus, 3rd edn, John Wiley and Sons Ltd, Chichester, 2004, pp951-79.
• Clark A., Nilsson MR Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes? Diabetologia 2004;47:157-69.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• In't Veld PA, Zhang F., Madsen OD, Kloppel G. Islet amyloid polypeptide immunoreactivity in the human fetal pancreas. Diabetologia 1992;35: 272-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Koda JE, Fineman MS, Kolterman OG, Caro JF 24 hour plasma amylin profiles are elevated in IGT subjects vs. normal controls. Diabetes 1995; 44(suppl 1):238A.
• Weyer C., Maggs DG, Young AA, Kolterman OG Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control. Current Pharmaceutical Design 2001;7:1353-73.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Buse JB, Weyer C., Maggs DG Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach to overcome barriers with insulin therapy. Clinical Diabetes 2002;20:137-44.[Abstract/Free Full Text]
• Fineman M., Koda J., Lolterman O. Subcutaneous administration of a human amylin analogue suppresses postprandial plasma glucagon concentrations in type 1 diabetic patients. Diabetes 1998;47(suppl 1):A89.
• Kong MF, Stubbs TA, King P. et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 1998;41:577-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Symlin prescriber information. www.symlin.com/docs/Symlin_PI_and_Med_Guide.pdf
• Kleppinger EL, Vivian EM Pramlintide for the treatment of diabetes mellitus. Ann Pharmacother 2003;37:1082-9.[Abstract/Free Full Text]
• Whitehouse F., Kruger DF, Fineman M. et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 2 diabetes. Diabetes Care 2002;25: 724-30.[Abstract/Free Full Text]
• Ratner RE, Want LL, Fineman MS et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002;4:63-5.[CrossRef][Medline] [Order article via Infotrieve]
• Heptulla RA, Rodriquez IM, Bomgaars L., Haymond MW The role of amylin and glucagons in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes 2005;54:1100-07.[Abstract/Free Full Text]
• Chapman I., Parker B., Doran S. et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005;48:838-48.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 3, 151-154 (2005)
DOI: 10.1177/14746514050050030701


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Early and intensive treatment: glycaemic control in type 2 diabetes Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 145 - 146. [PDF]

				C. Day and C. J Bailey Review: Pharmacological approaches to reduce adiposity The British Journal of Diabetes & Vascular Disease, May 1, 2006; 6(3): 121 - 125. [Abstract] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Day, C. Search for Related Content Social Bookmarking                         What's this?